Simple Test Predicts Childhood Cancer Relapse
|
By LabMedica International staff writers Posted on 26 May 2016 |

Image: The IncuCyte zoom continuous live-cell imaging and analysis system (Photo courtesy of Essen Biosciences).
High-risk neuroblastoma, which occurs mostly in children under five, is treated with surgery and chemotherapy, and neuroblastomas currently rated low risk are just removed or left untreated while doctors 'wait and see', but a fraction of low risk tumors recur and ultimately kill.
A cheap simple test could accurately predict the recurrence of a childhood cancer, as a protein marker has been pinpointed which when absent, shows neuroblastoma is almost certain to recur. It means children with low-risk neuroblastoma, who do not have the biomarker, can be reclassified as at high risk of relapse and have chemotherapy earlier.
Scientists at Brunel University London (UK) and their colleagues collected a retrospective series of primary tumors from neuroblastoma (NB) patients. Formalin-fixed, paraffin-embedded tissue sections from NB tumors were studied. Each tumor area tested contained malignant cells, assessed by histological examination. Quantification of immunofluorescence- or DAB-positive tumor cells was performed on serial tumor tissue sections. Tumor cells were distinguished in the samples using NB-specific marker, the homophilic binding glycoprotein neural cell adhesion molecule (NCAM, CD56).
The scientists carried out cell proliferation assays using IncuCyte live-cell imaging system (Essen Biosciences, Ann Arbor, MI, USA); immunostaining of cultured cells; Western blotting; angiogenesis assays where the images were captured using JuLI smart fluorescent cell analyzer (Baker Ruskinn, Sanford, ME; USA). The investigators used several other methodologies to identify the Promyelocytic Leukaemia protein-1(PML-1) and gene expression was assessed using chip microarrays.
PML was detected in the developing and adult sympathetic nervous system, whereas it was not expressed or low in metastatic neuroblastoma tumors. Reduced PML expression in patients with low-risk cancers, i.e. localized and negative for the V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog (MYCN) protooncogene was strongly associated with tumor recurrence. PML-I, but not PML-IV, isoform suppresses angiogenesis via upregulation of thrombospondin-2 (TSP-2), a key inhibitor of angiogenesis. Finally, PML-I and TSP-2 expression inversely correlates with tumor angiogenesis and recurrence in localized neuroblastomas.
Paolo Salomoni, PhD, a professor and senior author of the study said, “We have found the absence of PML a very precise marker of tumor recurrence. In the low risk tumors, the absence of PML will be a very useful marker. What we can now say is that even some tumors classified as low risk, that would have previously gone untreated, if they show no expression of PML, they ought now to be classified as high risk.” The study was published on April 13, 2016, in the journal Clinical Cancer Research.
Related Links:
Brunel University London
Essen Biosciences
Baker Ruskinn
A cheap simple test could accurately predict the recurrence of a childhood cancer, as a protein marker has been pinpointed which when absent, shows neuroblastoma is almost certain to recur. It means children with low-risk neuroblastoma, who do not have the biomarker, can be reclassified as at high risk of relapse and have chemotherapy earlier.
Scientists at Brunel University London (UK) and their colleagues collected a retrospective series of primary tumors from neuroblastoma (NB) patients. Formalin-fixed, paraffin-embedded tissue sections from NB tumors were studied. Each tumor area tested contained malignant cells, assessed by histological examination. Quantification of immunofluorescence- or DAB-positive tumor cells was performed on serial tumor tissue sections. Tumor cells were distinguished in the samples using NB-specific marker, the homophilic binding glycoprotein neural cell adhesion molecule (NCAM, CD56).
The scientists carried out cell proliferation assays using IncuCyte live-cell imaging system (Essen Biosciences, Ann Arbor, MI, USA); immunostaining of cultured cells; Western blotting; angiogenesis assays where the images were captured using JuLI smart fluorescent cell analyzer (Baker Ruskinn, Sanford, ME; USA). The investigators used several other methodologies to identify the Promyelocytic Leukaemia protein-1(PML-1) and gene expression was assessed using chip microarrays.
PML was detected in the developing and adult sympathetic nervous system, whereas it was not expressed or low in metastatic neuroblastoma tumors. Reduced PML expression in patients with low-risk cancers, i.e. localized and negative for the V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog (MYCN) protooncogene was strongly associated with tumor recurrence. PML-I, but not PML-IV, isoform suppresses angiogenesis via upregulation of thrombospondin-2 (TSP-2), a key inhibitor of angiogenesis. Finally, PML-I and TSP-2 expression inversely correlates with tumor angiogenesis and recurrence in localized neuroblastomas.
Paolo Salomoni, PhD, a professor and senior author of the study said, “We have found the absence of PML a very precise marker of tumor recurrence. In the low risk tumors, the absence of PML will be a very useful marker. What we can now say is that even some tumors classified as low risk, that would have previously gone untreated, if they show no expression of PML, they ought now to be classified as high risk.” The study was published on April 13, 2016, in the journal Clinical Cancer Research.
Related Links:
Brunel University London
Essen Biosciences
Baker Ruskinn
Latest Pathology News
- Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
- AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
- New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
- Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
- Review Highlights Progress and Validation Needs for AI in Digital Pathology
- Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
- AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
- Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
- AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
- AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
- AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
- AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
- Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
- Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
- AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
- Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreMolecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







